Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1155520100050010038
Anesthesia and Pain Medicine
2010 Volume.5 No. 1 p.38 ~ p.44
Controlling deliberate hypotension in hypertensive patients undergoing spinal surgery: a comparison between remifentanil and sodium nitroprusside
Park Sang-Hyun

Do Sang-Hwan
Kim Chong-Soo
Ro Young-Jin
Han Sung-Hee
Kim Jin-Hee
Han Kyoung-Ah
Abstract
Background: This study was designed to determine whether remifentanil or sodium nitroprusside (SNP) with sevoflurane anesthesia can induce safe deliberate hypotension (DH) to a target mean arterial pressure (MAP) of 55?65 mmHg in patients with controlled hypertension.

Methods: Thirty patients with controlled hypertension and who were scheduled for posterior lumbar interbody fusion were randomly assigned to receive remifentanil (n = 15, group R) or SNP (n = 15, group S).All the patients received a balanced anesthetic technique including 1.5?2 vol% sevoflurane.Group R received remifentanil by target-controlled infusion.The infusion was initiated with a target concentration at 4 ng/ml and this was adjusted every 1 min by 1 ng/ml to maintain the MAP to the target level of 55?65 mmHg.In group S, the infusion of SNP was initiated at 1 ug/kg/min and this was increased by 0.5 ug/kg/min.Cerebral oximetry was done and the cardiac index was measured with esophageal Doppler.

Results: DH was achieved at a MAP = 60 mmHg within 5.7 min for group R and 3.7 min for group S.The intraoperative blood loss was lower in Group R than that in Group S (304 ¡¾ 103 vs 650 ¡¾ 141 ml, P £¼ 0.05).The frequency of added ephedrine injection to control the MAP and discontinuation of the study drug due to a MAP £¼ 60 mmHg were higher in group S than in group R (46% vs 13%, P £¼ 0.05 and 62% vs 20%, P £¼ 0.05, respectively).

Conclusions: Compared to SNP, remifentanil with sevoflurane anesthesia induced safer DH for patients with controlled hypertension.
KEYWORD
Deliberate hypotension, Remifentanil, Sodium nitroprusside
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø